secwatch.observer — SEC 8-K summary
======================================

Issuer:     BOSTON SCIENTIFIC CORP (BSX)
CIK:        0000885725
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0000885725-26-000017
Event type: debt
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 1.02, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Boston Scientific enters $11B credit facilities; $8B committed for Penumbra acquisition
--------------------------------------------------------------------------------

- $3.0B revolving credit agreement matures Feb 2031 with two one-year extension options.
- $2.0B 364-day revolving credit agreement tied to Penumbra acquisition; matures 364 days post-close.
- $6.0B term loan agreement: $1B Tranche A and $5B Tranche B, both 364-day delayed draw at closing.
- Tranche B Loans must be prepaid with net proceeds from equity or debt issuance after closing.
- Prior $3.0B 2021 revolving credit agreement terminated upon entry into the new facilities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/885725/000088572526000017/0000885725-26-000017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/885725/000088572526000017/bsx-20260226.htm
  HTML page:      https://secwatch.observer/filing/0000885725-26-000017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer